Companies formed
Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
Quantum Fabrix
Weaving perfect components into quantum technology solutions.
Incorporated in October 2024
Origin: Oxford University, Department of Physics
Porpoise Power
Using bio-inspired hydropower systems to generate power which is then converted to electricity.
Incorporated in September 2024
Origin: Oxford University, Department of Biology
Granza Bio Corporation
A new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.
Incorporated in July 2024
Origin: Oxford University, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Ascension Earth Resources
Oxford StemTech
Incorporated in June 2024
Origin: Oxford University, Nuffield Department of Clinical Neurosciences
Eterna Biologics
Harnessing the power of CRISPR to develop the next generation of RNA therapeutics.
Incorporated in June 2024
TheraCryf
Developing innovative therapeutics in oncology and behavioural brain disorders.
Incorporated in April 2024
NantBio
Developing treatments using molecularly targeted drugs tailored to the specific molecular profile of a patient's tumour.
Incorporated in April 2024
Ramanomics
Diagnostics built on a Raman-spectroscopy-powered single cell identification for bacteria and fungi.
Incorporated in April 2024
RQBio Covid
Developing monoclonal antibodies for instant, long-lasting immunity, protecting vulnerable people from infectious diseases.
Incorporated in April 2024
Yellowstone Biosciences
Commercialising T cell receptor-based immunotherapy for multiple indications.
Incorporated in March 2024
Origin: Oxford University, Radcliffe Department of Medicine (RDM)
Kodiform Therapeutics
FlexSR
A new approach to automatic speech recognition technology.
Incorporated in February 2024
Origin: Oxford University
2023
MatchBio
MatchBio's technology can improve the function of antigen receptors, for example by tuning their antigen sensitivity of their existing products.
Incorporated in August 2023
Origin: Oxford University, Sir William Dunn School of Pathology
Alveogene
The advancement, through pre-clinical and clinical trials, the development a number of lentiviral-based gene therapies for respiratory diseases.
Incorporated in July 2023
Origin: Oxford University, Nuffield Department of Clinical Laboratory Sciences